publication venue for
- Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment—A nationwide register‐based study. 294:743-760. 2023
- Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia. 293:309-328. 2023
- Variations in end‐of‐life care practices in older critically ill patients with COVID‐19 in Europe. 292:438-449. 2022
- One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals. 292:103-115. 2022
- Prognostic significance of present atrial fibrillation on a single office electrocardiogram in patients with atrial fibrillation. 289:395-403. 2021
- Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE‐LY trial. 283:282-292. 2018
- Myalgic encephalomyelitis: International Consensus Criteria. 282:353-353. 2017
-
Low resting heart rates are associated with new‐onset atrial fibrillation in patients with vascular disease: results of the
ONTARGET /TRANSCEND studies. 278:303-312. 2015 -
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the
ONTARGET andTRANSCEND studies. 278:38-49. 2015 - An emerging double burden of disease: the prevalence of individuals with cardiovascular disease and cancer. 275:494-505. 2014
- Advantages and limitations of the new anticoagulants. 275:1-11. 2014
- Using Mendelian randomization to determine causative factors in cardiovascular disease. 273:44-47. 2013
- Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. 271:15-24. 2012
- Myalgic encephalomyelitis: International Consensus Criteria. 270:327-338. 2011
- New aspects on treatment modalities for thromboembolic episodes. 268:109-119. 2010
- Identifying women with severe angiographic coronary disease. 268:66-74. 2010
- Low PAI‐1 activity in relation to inflammatory parameters, insulin profile and body mass index. 264:586-592. 2008
- Response to: the ethical problem and the risk of haemorrhage. 264:503-503. 2008
- Clinical factors influencing the sensitivity to warfarin when restarted after surgery. 263:412-419. 2008
- Renin–angiotensin and endothelial nitric oxide synthase gene polymorphisms are not associated with the risk of incident type 2 diabetes mellitus: a prospective cohort study. 263:376-385. 2008
- Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double‐blind trial. 261:276-284. 2007
- Temporal trends in the incidence of HIV infection in antenatal clinic attendees in Addis Ababa, Ethiopia, 1995–2003. 261:132-137. 2007
- Cost‐effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long‐term model based on the cure trial. 255:562-570. 2004
- Novel anticoagulant agents: introduction. 254:308-312. 2003
- The evolution of the randomized controlled trial and its role in evidence‐based decision making. 254:105-113. 2003
- Acquired platelet dysfunction may be an aetiologic factor in Heyde's syndrome – normalization of bleeding time after aortic valve replacement. 252:516-523. 2002
- Author’s reply. 250:260-261. 2001
- Liver fibrosis attributed to lipid lowering medications: two cases. 250:249-254. 2001
- Utility of ultrasound imaging of the lower extremities in the diagnostic approach in patients with suspected pulmonary embolism. 250:262-264. 2001
- The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. 247:601-606. 2000
- The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. The DURAC Trial Study Group.. 247:601-606. 2000
- Introduction. 245:367-368. 1999
- Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings. 245:399-399. 1999
- Oral anticoagulation – how intense and for how long?. 245:365-366. 1999
- A simple clinical model for the diagnosis of deep‐vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. 243:15-23. 1998
- The present status of thrombolytic treatment in noncardiac disorders. 236:447-454. 1994
- Quality of oral anticoagulant control and treatment in Sweden. 236:143-152. 1994
- Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group.. 236:143-152. 1994
- Haemorrhagic and Thromboembolic Complications versus Intensity of Treatment of Venous Thromboembolism with Oral Anticoagulants. 224:425-430. 1988
- Long‐term Sequelae of Calf Vein Thrombosis Treated with Heparin or Low‐dose Streptokinase. 219:349-357. 1986
- The Duration of Oral Anticoagulation after Deep Vein Thrombosis. 217:547-552. 1985
- Hepatitis, Epidemiology and Liver Function in Hemophiliacs in Sweden. 215:249-256. 1984
- Factors of Importance for QRS Complex Recovery after Acute Myocardial Infarction. 211:157-162. 1982